Thiogenesis Therapeutics, Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is developing sulfur-containing prodrugs that act as precursors with the potential to treat serious pediatric diseases with unmet medical needs. Its lead compound, TTI-0102, is a disulfide, made up of two thiols that lead to two independent cysteamine molecules. Cysteamine is a thiol that has been rigorously studied and tested. TTI-0102 has been developed to address the obstacles facing previous thiol-based drugs, their short half-lives and side effects. As a prodrug, TTI-0102 is metabolized into cysteamine molecules after it is ingested. The metabolic process acts as a gating mechanism that eliminates the spike in the immediate release of cysteamine that is commonly linked to GI side effects. TTI-0102â€™s initial applications are for mitochondrial encephalopathy, lactic acidosis and stroke-like episodes, Leigh syndrome, Rett syndrome and pediatric Nonalcoholic steatohepatitis.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
15/26/15	CA$0.5300	-7.02%	5,500
14/26/14	CA$0.5700	+1.79%	500

Delayed Quote Toronto S.E.

More quotes

Income Statement and Estimates

More financial data

Net sales - Rate of surprise

Company calendar

Market Closed - Toronto S.E. Other stock markets 07:54:19 15/07/2026 pm IST			5-day change	1st Jan Change
0.5300 ^CAD	-7.02%		-7.02%	-18.46%

13/07	Thiogenesis Therapeutics Receives Fda Rare Pediatric Disease Designation for Tti-0102 for the Treatment of Leigh Syndrome	CI
13/07	Thiogenesis Therapeutics' Treatment For Leigh Syndrome Receives FDA Rare Pediatric Disease Designation	MT

Market Cap	2.75Cr 1.96Cr 1.71Cr 1.58Cr 1.45Cr 188.18Cr 2.79Cr 19Cr 7.39Cr 92Cr 7.34Cr 7.18Cr 317.02Cr	P/E 2024	-8.65x	P/E 2025	-4.25x
Enterprise Value	2.59Cr 1.84Cr 1.61Cr 1.48Cr 1.36Cr 177.11Cr 2.63Cr 18Cr 6.95Cr 87Cr 6.91Cr 6.76Cr 298.37Cr	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	87.27%	Yield 2024 *	-	Yield 2025	-

13/07	Thiogenesis Therapeutics Receives Fda Rare Pediatric Disease Designation for Tti-0102 for the Treatment of Leigh Syndrome	CI
13/07	Thiogenesis Therapeutics' Treatment For Leigh Syndrome Receives FDA Rare Pediatric Disease Designation	MT
17/06	Thiogenesis Therapeutics Appoints Gilad Aharon to its Board	MT
17/06	Thiogenesis Therapeutics, Corp. Appoints Gilad Aharon to Its Board of Directors	CI
03/06	Thiogenesis Therapeutics, Corp. announced that it has received CAD 9.07185 million in funding	CI
26/05	Thiogenesis Therapeutics, Corp. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
11/05	Thiogenesis Therapeutics to Raise $8 Million Via a Non-Brokered Private Placement	MT
11/05	Thiogenesis Therapeutics, Corp. announced that it expects to receive CAD 8 million in funding	CI
01/05	Thiogenesis Therapeutics, Corp. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
30/04	Thiogenesis Therapeutics, Corp. Auditor Raises 'Going Concern' Doubt	CI
02/02	Thiogenesis Therapeutics, Corp. Provides Program Update	CI
23/01	Thiogenesis Therapeutics, Corp. Announces the Presentation of Interim Data from Its Phase 2 (Eu) Clinical Study of Tti-0102 in Patients with Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Episodes At Mitocon 2026	CI
27/11	Thiogenesis Therapeutics, Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI

13/07	Thiogenesis Receives FDA Rare Pediatric Disease Designation for TTI-0102 for the Treatment of Leigh Syndrome	NE
17/06	Thiogenesis Appoints Dr. Gilad Aharon to Its Board of Directors	NE
03/06	Thiogenesis Closes Oversubscribed Non-Brokered Private Placement for Gross Proceeds of C$9.07 Million	NE
02/06	Thiogenesis Upsizes Non-Brokered Private Placement of Common Shares	NE
11/05	Thiogenesis Announces Non-Brokered Private Placement	NE

Thiogenesis Therapeutics, Corp. Share Price

Stocks

TTI

CA88410L1022

Biotechnology & Medical Research

Valuation: Thiogenesis Therapeutics, Corp.

Chart: Thiogenesis Therapeutics, Corp.

Latest news : Thiogenesis Therapeutics, Corp.

Analysts' recommendations: Thiogenesis Therapeutics, Corp.

Press Releases: Thiogenesis Therapeutics, Corp.

Quotes and Performance

Course Extremes

Managers and Directors: Thiogenesis Therapeutics, Corp.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Net sales - Rate of surprise

1 day	-7.02%
1 week	-7.02%
Current month	-1.85%
1 month	-7.02%
3 months	-10.17%
6 months	-13.11%
Current year	-18.46%

1 week	0.53	0.57
1 month	0.53	0.59
Current year	0.44	0.66
1 year	0.44	0.87
3 years	0.44	1.06
5 years	0.38	1.06
10 years	0.38	1.06

Manager	Title	Age	Since
Patrice Rioux CEO	Chief Executive Officer	75	31/03/2022
Brook Riggins CEO	Chief Executive Officer	60	-

Director	Title	Age	Since
Kim Tsuchimoto BRD	Director/Board Member	63	31/03/2022
Christopher Starr CHM	Chairman	73	31/03/2022
Brook Riggins BRD	Director/Board Member	60	03/05/2018

Date	Insider	Type	Main position	Quantity	% Market Cap.
01/06	W. Mullally	Sell	Director	1,50,000	0.2894%
11/25/11	W. Mullally	Option	Director	75,000	0.1702%
01/25/01	W. Mullally	Sell	Director	64,000	0.1453%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
THIOGENESIS THERAPEUTICS, CORP.	-7.02%	-7.02%	-33.75%	-19.70%	1.96Cr
LONZA GROUP AG	-0.17%	+1.47%	+3.16%	+6.80%	5.03TCr
REVOLUTION MEDICINES, INC.	-0.29%	-2.81%	+387.81%	+591.82%	3.92TCr
IQVIA HOLDINGS INC.	-0.49%	+1.48%	+31.16%	-6.46%	3.45TCr
BEONE MEDICINES AG	+1.53%	+3.11%	+15.41%	+58.54%	3.46TCr
CELLTRION, INC.	+1.68%	-0.62%	+3.30%	+27.34%	2.7TCr
ASCENDIS PHARMA A/S	+1.13%	-3.11%	-	-	1.67TCr
MEDPACE HOLDINGS, INC.	-1.29%	-0.52%	+69.24%	+117.60%	1.51TCr
EUROFINS SCIENTIFIC SE	+0.43%	+3.34%	+14.96%	+17.46%	1.39TCr
ICON PUBLIC LIMITED COMPANY	+2.45%	+3.99%	+18.20%	-30.12%	1.32TCr
Average	-0.20%	+0.84%	+56.61%	+84.81%	2.45TCr
Weighted average by Cap.	+0.40%	+0.83%	+81.43%	+121.60%

	2024	2025
Net sales	-	-
Net income	-31.46L -22.39L -19.58L -18.06L -16.6L -22Cr -32L -2.16Cr -84.6L -11Cr -84.09L -82.25L -36Cr	-74.26L -52.86L -46.22L -42.64L -39.19L -51Cr -75.53L -5.09Cr -2Cr -25Cr -1.99Cr -1.94Cr -86Cr
Net Debt	-38.48L -27.39L -23.95L -22.09L -20.31L -26Cr -39.14L -2.64Cr -1.03Cr -13Cr -1.03Cr -1.01Cr -44Cr	-16.16L -11.5L -10.06L -9L -9L -11Cr -16.44L -1.11Cr -43.46L -5.41Cr -43.2L -42.25L -19Cr